Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GLP1R | P43220 | 8/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26129806 | 0.89 | ALDH1A1 (0.41) | EPHX2ALDH1A1TSHRTHRBMEN1 | |
| SCHEMBL6317524 | 0.84 | KDM4E (0.35) | EPHX2ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL7268276 | 0.82 | SMN1; SMN2 (0.38) | EPHX2ALDH1A1TSHRTHRBMEN1 | |
| SCHEMBL27386798 | 0.82 | SMN1; SMN2 (0.38) | EPHX2ALDH1A1TSHRTHRBMEN1 | |
| SCHEMBL30971878 | 0.81 | EPHX2 (0.42) | EPHX2ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL18251468 | 0.81 | EPHX2 (0.42) | EPHX2ALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL16538964 | 0.81 | EPHX2 (0.34) | EPHX2ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL2865428 | 0.80 | ALDH1A1 (0.50) | EPHX2ALDH1A1TSHRTHRBCYP2C19 | |
| SCHEMBL22609510 | 0.80 | ALDH1A1 (0.50) | EPHX2ALDH1A1TSHRTHRBCYP2C19 | |
| SCHEMBL6275021 | 0.80 | ALDH1A1 (0.50) | EPHX2ALDH1A1TSHRTHRBCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114901673-B | Preparation method of solution phase peptide nucleic acid oligomer | 海阳生物材料有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20230108350-A1 | METHOD FOR PRODUCING PNA OLIGOMER IN SOLUTION PROCESS | SEASUNBIO MATERIALS (KP) | 2023-04-06 | — | — | US | disclosed |
| EP-4083054-A1 | METHOD FOR PRODUCING PNA OLIGOMER IN SOLUTION PROCESS | Seasunbio Materials (KR) | 2022-11-02 | — | — | EP | disclosed |
| CN-114901673-A | Method for preparing solution phase peptide nucleic acid oligomer | 海阳生物材料有限公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-2021133033-A1 | METHOD FOR PRODUCING PNA OLIGOMER IN SOLUTION PROCESS | 주식회사 시선바이오머티리얼스 | 2021-07-01 | — | — | WO | disclosed |
| US-9469656-B2 | HDAC inhibitors as anti-cancer agents | THE UNIVERSITY OF TOLEDO (US) | 2016-10-18 | — | — | US | disclosed |
| US-20150329560-A1 | HDAC Inhibitors as Anti-Cancer Agents | THE UNIVERSITY OF TOLEDO (US) | 2015-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230108350-A1 | METHOD FOR PRODUCING PNA OLIGOMER IN SOLUTION PROCESS | NCL, POLI, RNGTT | EPHX2 2415/4885ALDH1A1 4771/4885TSHR 2920/4885 |
| US-20150329560-A1 | HDAC Inhibitors as Anti-Cancer Agents | HDAC1, HDAC4, HDAC5 | EPHX2 2766/4885ALDH1A1 1221/4885TSHR 4383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.